Find clinical trials for Non-Small-Cell Lung Cancer in New Haven, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Small-Cell Lung Cancer trials near New Haven, CT, USA:
body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) t...
Phase 2
Hartford, Connecticut, United States of America and 8 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...
Phase 2
Port Jefferson, New York, United States and 83 other locations
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI...
Phase 3
Brewster, New York, United States and 9 other locations
PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....
Phase 2
New Haven, Connecticut, United States and 126 other locations
in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...
Phase 3
Port Jefferson Station, New York, United States and 200 other locations
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...
Phase 2
New Haven, Connecticut, United States and 137 other locations
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...
Phase 3
Shirley, New York, United States and 230 other locations
and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal ant...
Phase 1
New Haven, Connecticut, United States and 2 other locations
and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...
Phase 1
New Haven, Connecticut, United States and 30 other locations
and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non...
Phase 1
Norwalk, Connecticut, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal